Clearside Biomedical Inc.

Clearside Biomedical develops suprachoroidal eye therapies, including Phase 2 CLS‑AX for wet AMD and XIPERE for macular edema. Partnerships with Regenxbio, BioCryst, and others underscore growth potential in the niche ophthalmic market.

Headquarters: United States (USA)

Website: Visit Site 🔗
Type: Corporation

Company Profile

Sector: Professional Services
Industry: Biotechnology Research

Employees: 32
HQ: Alpharetta

Unlock the full potential.

Get access to Relative P/E Ratio Valuation Histogram.

Upgrade

Traded Instruments

+ Add Instrument 1

Symbol	Name	Type	Exchange	Currency	ISIN	Status	Actions
CLSD	Clearside Biomedical Inc. Cap: 0.0B	EQUITY	NMS	USD	US1850631045	Active	📈